THE ATHEROSCLEROSIS PREVENTION IN PEDIATRIC LUPUS ERYTHEMATISIS (APPLE) STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 系统性红斑狼疮(SLE)是一种罕见的、潜在威胁生命的自身免疫性疾病，其血管炎症遍布全身。在儿童中，最常见的器官是皮肤、关节、肾脏、心脏和大脑。一般来说，儿童系统性红斑狼疮比成人更严重，因为更多的器官受到影响，影响更严重。 动脉粥样硬化是一种在老年人中常见的疾病，是由脂肪沉积到血管内壁引起的血管狭窄引起的。动脉粥样硬化会增加心肌梗死和中风的风险。降脂药物可以降低血液中的脂肪含量，防止更多的脂肪粘在血管内壁上，也可能会溶解血管上的脂肪沉积。这些药物已被证明可以降低心脏病发作和中风的风险。 由于血管发炎和身体处理脂肪的方式异常，系统性红斑狼疮患者更有可能在较早的年龄患上动脉粥样硬化。系统性红斑狼疮患者患心肌梗死和中风的风险增加。在这项研究中，我们计划评估患有SLE的儿童和青少年在三年内发生动脉粥样硬化的情况。此外，+的受试者将服用降脂剂，+的受试者将服用安慰剂。我们希望这一结果表明，服用降脂剂的儿童较少患上动脉粥样硬化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Systemic Lupus Erythematosus (SLE) is an uncommon, potentially life-threatening, autoimmune disease of inflammation of the blood vessels all over the body. In children, the most common organs affected are the skin, the joints, the kidney, the heart and the brain. In general, childhood SLE is more severe than it is in adults because more organs are affected and affected more severely. Atherosclerosis is a disease common in older adults and is caused by a narrowing of the blood vessels caused by fatty deposits to the lining of the vessels. Atherosclerosis increases the risk of cardiac infarction and stroke. Lipid-lowering drugs lower the fat content in blood, prevent further fat from sticking to the lining of blood vessels and also may dissolve fatty deposit on blood vessels. These drugs have been shown to reduce the risk of heart attack and stroke. Because of the inflammation in their blood vessels and abnormalities in the way their bodies handle fat, patients with SLE are more likely to develop atherosclerosis at an earlier age. Patients with SLE are at an increase risk for cardiac infarction and stroke. In this study, we plan to assess children and adolescents with SLE for the development of atherosclerosis over a period of three years. Additionally, + of the study subjects will take a lipid-lowering agent and + of the subjects will take a placebo. We hope the show that the children who take the lipid-lowering agent develop less atherosclerosis.